Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Week in Review: TAVR linked to higher reintervention risk | CCTA an essential tool | New PE guidelines | Delaying payment cuts
Saturday, February 21, 2026
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

This Week’s News

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 

READ MORE >
Medtronic's Evolut Pro TAVR valve is designed to treat aortic stenosis.
Share on Twitter Share on Facebook Share on Linkedin

TAVR linked to higher reintervention rate than SAVR in Evolut Low Risk trial update

Share on Twitter Share on Facebook Share on Linkedin
Medtronic's Evolut Pro TAVR valve is designed to treat aortic stenosis.
The Evolut Low Risk trial has been one of cardiology’s most closely watched studies for years now. For the first five years after treatment, TAVR and SAVR were associated with comparable outcomes when treating low-risk patients. In this new six-year update, however, TAVR was linked to a heightened risk of reintervention not seen with SAVR. 
READ MORE >

Cardiologist develops new heart device that uses gel to reduce stroke risk in AFib patients

After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.

READ MORE >
After years of implanting left atrial appendage occlusion (LAAO) devices in atrial fibrillation (AFib) patients, an interventional cardiologist with the University of Chicago Medical Center (UChicago Medicine) has developed a new device that could be a more affordable alternative to Boston Scientific’s Watchman and Abbott’s Amplatzer Amulet LAA Occluder.
Share on Twitter Share on Facebook Share on Linkedin

Cardiologist develops new heart device that uses gel to reduce stroke risk in AFib patients

Share on Twitter Share on Facebook Share on Linkedin
After years of implanting left atrial appendage occlusion (LAAO) devices in atrial fibrillation (AFib) patients, an interventional cardiologist with the University of Chicago Medical Center (UChicago Medicine) has developed a new device that could be a more affordable alternative to Boston Scientific’s Watchman and Abbott’s Amplatzer Amulet LAA Occluder.
After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.
READ MORE >

CCTA becoming an essential tool for interventional cardiologists

Ziad Ali, MD, explains how coronary computed tomography angiography is creating a major shift in cardiac care.

READ MORE >
iad Ali, MD, DPhil, director of the DeMatteis Cardiovascular Institute and director investigational interventional cardiology, St. Francis Hospital and Heart Center, explains how coronary computed tomography angiography (CCTA) offers a shift in cardiac care and interventional cardiology because of the information it offers on plaque burden and ischemia based on fractional flow reserve CT (FFR-CT). #TCT #YesCCT
Share on Twitter Share on Facebook Share on Linkedin

CCTA becoming an essential tool for interventional cardiologists

Share on Twitter Share on Facebook Share on Linkedin
iad Ali, MD, DPhil, director of the DeMatteis Cardiovascular Institute and director investigational interventional cardiology, St. Francis Hospital and Heart Center, explains how coronary computed tomography angiography (CCTA) offers a shift in cardiac care and interventional cardiology because of the information it offers on plaque burden and ischemia based on fractional flow reserve CT (FFR-CT). #TCT #YesCCT
Ziad Ali, MD, explains how coronary computed tomography angiography is creating a major shift in cardiac care.
READ MORE >

Statin labeling should be revised with updated warnings, meta-analysis confirms

Researchers explored data from more than 123,000 patients, noting that dozens of the adverse complications included on current labels can safely be removed. 

READ MORE >
Continuous and high-adherent statin users had lower baseline arterial stiffness which also grew more slowly over time, a new JAMA Network Open study finds.
Share on Twitter Share on Facebook Share on Linkedin

Statin labeling should be revised with updated warnings, meta-analysis confirms

Share on Twitter Share on Facebook Share on Linkedin
Continuous and high-adherent statin users had lower baseline arterial stiffness which also grew more slowly over time, a new JAMA Network Open study finds.
Researchers explored data from more than 123,000 patients, noting that dozens of the adverse complications included on current labels can safely be removed. 
READ MORE >

First ACC/AHA acute pulmonary embolism guidelines include new categories for risk stratification

The new guidance, the first of its kind, focuses on the importance of making a prompt diagnosis and providing care as quickly as possible. While some PE patients with mild cases can be discharged early, others may require an immediate catheter-based intervention or surgery.

READ MORE >
American Heart Association and Joint Commission launch new Comprehensive Heart Attack Center certification.
Share on Twitter Share on Facebook Share on Linkedin

First ACC/AHA acute pulmonary embolism guidelines include new categories for risk stratification

Share on Twitter Share on Facebook Share on Linkedin
American Heart Association and Joint Commission launch new Comprehensive Heart Attack Center certification.
The new guidance, the first of its kind, focuses on the importance of making a prompt diagnosis and providing care as quickly as possible. While some PE patients with mild cases can be discharged early, others may require an immediate catheter-based intervention or surgery.
READ MORE >

Universal heart screening for all athletes? Not so fast, cardiologists warn

Mandates for universal ECG screening are gaining momentum as a way to combat the risk of SCA. However, the ACC warned, modern healthcare systems were not built to withstand such a rise in demand. These mandates will also result in higher costs and other unintended consequences.

READ MORE >
cardiologist time out
Share on Twitter Share on Facebook Share on Linkedin

Universal heart screening for all athletes? Not so fast, cardiologists warn

Share on Twitter Share on Facebook Share on Linkedin
cardiologist time out
Mandates for universal ECG screening are gaining momentum as a way to combat the risk of SCA. However, the ACC warned, modern healthcare systems were not built to withstand such a rise in demand. These mandates will also result in higher costs and other unintended consequences.
READ MORE >

How hypertension during pregnancy impacts a woman's long-term cardiovascular health

Emerging research suggests that the early postpartum period may represent a critical window for influencing a woman's long-term cardiovascular health. 

READ MORE >
Michael Honigberg, MD, MPP, a preventive cardiologist and cardiovascular researcher at Massachusetts General Hospital, explains how preeclampsia and gestational hypertension during pregnancy can elevate cardiovascular risks later in life and how to best manage these patients.
Share on Twitter Share on Facebook Share on Linkedin

How hypertension during pregnancy impacts a woman's long-term cardiovascular health

Share on Twitter Share on Facebook Share on Linkedin
Michael Honigberg, MD, MPP, a preventive cardiologist and cardiovascular researcher at Massachusetts General Hospital, explains how preeclampsia and gestational hypertension during pregnancy can elevate cardiovascular risks later in life and how to best manage these patients.
Emerging research suggests that the early postpartum period may represent a critical window for influencing a woman's long-term cardiovascular health. 
READ MORE >

FDA clears 12-lead, cable-free home ECG monitoring system

The new technology synthesizes signals from a credit card-sized device into a 12-lead ECG representation. 

READ MORE >
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a 12-lead electrocardiogram (ECG) synthesis software for home assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior "not substantially equivalent (NSE) determination.
Share on Twitter Share on Facebook Share on Linkedin

FDA clears 12-lead, cable-free home ECG monitoring system

Share on Twitter Share on Facebook Share on Linkedin
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a 12-lead electrocardiogram (ECG) synthesis software for home assessment of arrhythmias. This clearance follows HeartBeam’s successful appeal of a prior "not substantially equivalent (NSE) determination.
The new technology synthesizes signals from a credit card-sized device into a 12-lead ECG representation. 
READ MORE >

Cardiology, cardiac imaging groups support new bill delaying cuts to physician pay

Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.

READ MORE >
money cost cutting Medicare scissors dollar economics
Share on Twitter Share on Facebook Share on Linkedin

Cardiology, cardiac imaging groups support new bill delaying cuts to physician pay

Share on Twitter Share on Facebook Share on Linkedin
money cost cutting Medicare scissors dollar economics
Nearly 40 healthcare organizations signed a letter in support of the bipartisan legislation, noting that Medicare's “efficiency adjustment” decreases reimbursement during a challenging time for physicians.
READ MORE >

Medtronic reports rising sales for cardiovascular devices—PFA tech leads the way

Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.

READ MORE >
Among general cardiologists, for example, median compensation jumped nearly 8% from 2023 to 2024. Interventional cardiology and electrophysiology saw even larger jumps. Dollar money graphic showing increased finance.
Share on Twitter Share on Facebook Share on Linkedin

Medtronic reports rising sales for cardiovascular devices—PFA tech leads the way

Share on Twitter Share on Facebook Share on Linkedin
Among general cardiologists, for example, median compensation jumped nearly 8% from 2023 to 2024. Interventional cardiology and electrophysiology saw even larger jumps. Dollar money graphic showing increased finance.
Medtronic's third quarter included a boom in PFA sales and a significant investment in Anteris Technologies. CEO Geoff Martha said the company hopes to make an even bigger impact in the structural heart space as time goes on.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Week in Review: TAVR vs. SAVR | FDA clears AI tech | Payment model confusion | Private equity & cardiology | Injuries after PCI
Heart surgery kits recalled | Sex-specific outcomes after TAVR & SAVR | A new risk calculator | FDA clears tricuspid valve
Thousands of heart surgery kits recalled | TAVR for AR linked to 'encouraging' data | Carotid IVL | Progress for new HCM drug
AI company founded by cardiologist makes big splash | Getting clinicians on the same page | Kidney injuries after PCI
Sweeping TAVR changes on the way | Pushing back against AI-powered prior authorization | FDA highlights recall after injuries
Cardiologists added to payment model by mistake | Sex-specific outcomes after TAVR & SAVR | FDA clears new AI software
Private equity unlikely to dominate cardiology | Cardiology opposes Medicare AI prior authorization | New AATS leaders

Pagination

    • First page « First
    • Previous page ‹‹
    • Page 1
    • Current page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup